Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Circulating Biomarkers, Exosomes & Liquid Biopsy Asia 2019

Steve Soper's Biography



Steve Soper, Foundation Distinguished Professor, Director, Center of BioModular Multi-scale System for Precision Medicine, The University of Kansas, Adjunct Professor, Ulsan National Institute of Science & Technology

Professor Soper is currently Foundation Distinguished Professor in Chemistry and Mechanical Engineering at the University of Kansas, Lawrence. Prof. Soper also holds an appointment at Ulsan National Institute of Science and Technology in Ulsan, South Korea, where he is a World Class University Professor. He is also serving as a Science Advisor for a number of major worldwide companies. Prof. Soper is currently the Editor of the Americas for the Analyst and on the Editorial Board for Journal of Fluorescence and Journal of Micro- and Nanosystems. Prof. Soper is also serving as a permanent Member of the Nanotechnology study panel with the National Institutes of Health.

As a result of his efforts, Prof. Soper has secured extramural funding totaling >$93M and has published over 245 peer-reviewed manuscripts (h index = 62) and is the author of 14 patents. He is also the founder of a startup company, BioFluidica, which is marketing devices for the isolation and enumeration of circulating tumor cells. His list of awards includes Chemical Instrumentation by the American Chemical Society, the Benedetti-Pichler Award for Microchemistry, Fellow of the AAAS, Fellow of Applied Spectroscopy, Fellow of the Royal Society of Chemistry, R&D 100 Award, Distinguished Masters Award at LSU and Outstanding Scientist/Engineer in the state of Louisiana in 2001. Finally, Prof. Soper has granted 44 PhDs and 6 MS degrees to students under his mentorship. He currently heads a group of 15 researchers.

Steve Soper Image

Identification of Different Subpopulations of Circulating Tumor Cells in the Blood of Localized and Metastatic Cancer Patients Using Microfluidics

Monday, 9 September 2019 at 12:15

Add to Calendar ▼2019-09-09 12:15:002019-09-09 13:15:00Europe/LondonIdentification of Different Subpopulations of Circulating Tumor Cells in the Blood of Localized and Metastatic Cancer Patients Using MicrofluidicsCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com

Liquid biopsies are becoming an attractive source of biomarkers that can be used to manage a variety of cancer-related diseases. One of the principle biomarkers for oncology-related diseases found in blood is circulating tumor cells (CTCs). The challenge associated with using CTCs as biomarkers for many cancer-related diseases has been the modest clinical sensitivity demonstrated using the FDA-approved platform. CTCs expressing invasive phenotypes down-regulate epithelial antigens, such as the epithelial cell adhesion molecule – EpCAM, which is typically used for the affinity selection of CTCs. As such, CTCs may have a continuum of phenotypes and thus, a single selection marker may not address all cells comprising the tumor microenvironment. We have developed a CTC selection strategy that employs two polymeric microfluidic chips modified with antibodies and connected in series with each selecting a distinct CTC subpopulation from a single blood sample. In addition to the common marker used for CTC positive selection (EpCAM), Fibroblast Activation Protein alpha (FAPa) expressing CTCs can also be selected. Using the dual selection strategy, both CTC types were detected from patients with clinical sensitivity that showed significant improvement compared to selection in which only EpCAM was used. Approximately 90% of the selected CTCs were found not to co-express both antigens. Due to the high purity (>80%) and clinical yields (>95% recovery) of the dual selection strategy, molecular analysis of both EpCAM and FAP-alpha CTCs could be carried out including next generation sequencing, and droplet digital PCR. Our results suggest FAP-alpha and EpCAM CTCs can be used in concert to guide therapeutic decisions for cancer patients. In this presentation, I will discuss the microfluidic chips we use for the selection of CTCs, the clinical results secured using these chips, and the molecular profiling of both CTC subpopulations.


Add to Calendar ▼2019-09-09 00:00:002019-09-10 00:00:00Europe/LondonCirculating Biomarkers, Exosomes and Liquid Biopsy Asia 2019Circulating Biomarkers, Exosomes and Liquid Biopsy Asia 2019 in Seoul, KoreaSeoul, KoreaSELECTBIOenquiries@selectbiosciences.com